Intersphincteric resection versus abdominoperineal resection for lower rectal cancer: A systematic review and meta-analysis.

Surg OncolJul 8, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)

Zahra Ramezani, Ahmad Madankan, Vali Baigi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared intersphincteric resection (ISR) and abdominoperineal resection (APR) for lower rectal cancer in 4502 patients. ISR was associated with significantly lower rates of positive circumferential resection margin (CRM) and improved five-year overall survival (5YOS) (HR = 0.42, p < 0.001) compared to APR.

Key findings

  • ISR had a lower rate of positive CRM (RR: 0.41, p < 0.001) compared to APR.
  • Early postoperative complications were reduced with ISR (RR: 0.76, p < 0.001).
  • Local recurrence rates were lower in ISR patients (RR: 0.63, p = 0.0038).
  • Five-year overall survival was significantly better with ISR (HR = 0.42, p < 0.001).

Why it matters

The findings suggest that ISR may offer significant clinical advantages over APR for selected patients with lower rectal cancer, including better survival outcomes and fewer complications, which can inform surgical decision-making.

Source

PubMed · PMID 42435723

Published in Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.